LACK OF POTENTIATION OF VINCRISTINE-INDUCED NEUROTOXICITY BY VP-16-213

被引：16

作者：

JACKSON, DV ^{[1
]}

WELLS, HB ^{[1
]}

WHITE, DR ^{[1
]}

MUSS, HB ^{[1
]}

RICHARDS, F ^{[1
]}

COOPER, MR ^{[1
]}

STUART, JJ ^{[1
]}

POPE, EK ^{[1
]}

SPURR, CL ^{[1
]}

机构：

[1] WAKE FOREST UNIV,BOWMAN GRAY SCH MED,PIEDMONT ONCOL ASSOC,WINSTON SALEM,NC 27103

来源：

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS | 1983年 / 6卷 / 03期

关键词：

D O I：

10.1097/00000421-198306000-00013

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：327 / 330

页数：4

共 13 条

[1]

ARNOLD AM, 1979, CANCER CHEMOTH PHARM, V3, P71

[2]

CREASEY WA, 1975, ANTINEOPLASTIC IMMUN, V2, P670

[3]

FALKSON G, 1975, CANCER, V35, P1141, DOI 10.1002/1097-0142(197504)35:4<1141::AID-CNCR2820350418>3.0.CO

[4]

2-3

[5]

HANSEN MM, 1980, CANCER TREAT REP, V64, P1135

[6]

ISELL BF, 1979, CANCER TREAT REV, V6, P107

[7]

JACKSON DV, 1982, P AN M AM SOC CLIN, V1, P154

[8]

JACKSON DV, 1978, CLIN PHARM VINCA ALK, P227

[9]

ROZENCWEIG M, 1977, CANCER, V40, P334, DOI 10.1002/1097-0142(197707)40:1<334::AID-CNCR2820400147>3.0.CO

[10]

2-X